GILZ inhibits the mTORC2/AKT pathway in BCR-ABL + cells

Oncogene

Volumn 31, Issue 11, 2012, Pages 1419-1430

  Joha, S ^a   Nugues, A L ^a   Hetuin D ^a   Berthon, C ^a   Dezitter, X ^a   Dauphin, V ^a   Mahon, F X ^b   Roche Lestienne, C ^a   Preudhomme, C ^a   Quesnel, B ^a,c   Idziorek, T ^a  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

AKT; BCR ABL; dasatinib; GILZ; imatinib; mTORC2

Indexed keywords

BCR ABL PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIM PROTEIN; DASATINIB; DEXAMETHASONE; EPOXOMICIN; GLUCOCORTICOID; GLUCOCORTICOID INDUCED LEUCINE ZIPPER; IMATINIB; LEUCINE ZIPPER PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; SERINE; STAUROSPORINE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER RELAPSE; CANCER STEM CELL; CD34 SELECTION; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; MICE; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

MAMMALIA;

EID: 84858336307     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.328     Document Type: Article

References (54)

1. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. (2005). Identification of mcl-1 as a BCR/ABLdependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311.
2. Asselin-Labat ML, David M, Biola-Vidamment A, Lecoeuche D, Zennaro MC, Bertoglio J et al. (2004). GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin- 2 withdrawal-induced apoptosis. Blood 104: 215-223.
3. Ayroldi E,Migliorati G, Bruscoli S, Marchetti C, Zollo O, Cannarile L et al. (2001). Modulation of T-cell activation by the glucocorticoidinduced leucine zipper factor via inhibition of nuclear factor kappaB. Blood 98: 743-753.
4. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. (2002). Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 22: 7929-7941.
5. Ayroldi E, Zollo O, Bastianelli A, Marchetti C, Agostini M, Di Virgilio R et al. (2007). GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 117: 1605-1615.
6. Ayroldi E, Riccardi C. (2009). Glucocorticoid-induced leucine zipper (GILZ): A new important mediator of glucocorticoid action. Faseb J 23: 3649-3658.
7. Berrebi D, Bruscoli S, Cohen N, Foussat A, Migliorati G, Bouchet- Delbos L et al. (2003). Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: An anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 101: 729-738.
8. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H et al. (2010). Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 107: 12469-12474.
9. Cohen N, Mouly E, Hamdi H, Maillot MC, Pallardy M, Godot V et al. (2006). GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 107: 2037-2044.
10. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A et al. (1997). A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-Activated cell death. Immunity 7: 803-812.
11. Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler- Heitbrock L. (2003). Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol 74: 33-39.
12. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. (1997). Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 14: 507-513.
13. Delfino DV, Agostini M, Spinicelli S, Vito P, Riccardi C. (2004). Decrease of Bcl-xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice. Blood 104: 4134-4141.
14. Delfino DV, Spinicelli S, Pozzesi N, Pierangeli S, Velardi E, Bruscoli S et al. (2010). Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to SUMO-1 in murine thymocytes. Cell Death Differ 18: 183-190.
15. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L et al. (2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: Protein kinase Benhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 156: 531-542.
16. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS et al. (2005). Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24: 2317-2329.
17. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA et al. (2006). mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870.
18. Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST. (2008). Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol 110: 244-254.
19. Guertin DA, Sabatini DM. (2007). Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
20. Hicsonmez G. (2006). The effect of steroid on myeloid leukemic cells: The potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. Leuk Res 30: 60-68.
21. Hietakangas V, Cohen SM. (2007). Re-evaluating AKT regulation: Role of TOR complex 2 in tissue growth. Genes Dev 21: 632-637.
22. Ihle JN. (1985). Biochemical and biological properties of interleukin-3: A lymphokine mediating the differentiation of a lineage of cells that includes prothymocytes and mastlike cells. Contemp Top Mol Immunol 10: 93-119.
23. Ikenoue T, Hong S, Inoki K. (2009). Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol 452: 165-180.
24. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
25. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. (2003). Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 31: 11-17.
26. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM et al. (2008). Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118: 3038-3050.
27. Kolbus A, Blazquez-Domingo M, Carotta S, Bakker W, Luedemann S, von Lindern M et al. (2003). Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: Molecular analysis by expression profiling. Blood 102: 3136-3146.
28. Liu J, Joha S, Idziorek T, Corm S, Hetuin D, Philippe N et al. (2008). BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22: 791-799.
29. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. (2003). Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63: 5716-5722.
30. Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA. (2010). RAD 001 (everolimus) prevents mTOR and Akt late re-Activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 109: 320-328.
31. Martin J, Masri J, Bernath A, Nishimura RN, Gera J. (2008). Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun 372: 578-583.
32. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ et al. (2008). mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105: 10853-10858.
33. Miyoshi H, Ohki M, Nakagawa T, Honma Y. (1997). Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation. Leuk Res 21: 45-50.
34. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD et al. (2004). Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101: 3130-3135.
35. Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG et al. (2005). A potential role for hydrocortisone in the positive regulation of IL-15-Activated NK-cell proliferation and survival. Blood 106: 158-166.
36. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
37. Pocaly M, Lagarde V, Etienne G, Dupouy M, Lapaillerie D, Claverol S et al. (2008). Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics 8: 2394-2406.
38. Polak P, Hall MN. (2006). mTORC2 caught in a SINful Akt. Dev Cell 11: 433-434.
39. Sabatini DM. (2006). mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6: 729-734.
40. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
41. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
42. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
43. Saudemont A, Quesnel B. (2004). In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104: 2124-2133.
44. Saudemont A, Jouy N, Hetuin D, Quesnel B. (2005). NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTLmediated lysis and can express B7-H1 that stimulates T cells. Blood 105: 2428-2435.
45. Saudemont A, Hamrouni A, Marchetti P, Liu J, Jouy N, Hetuin D et al. (2007). Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 67: 4491-4498.
46. Schmidt M, Lugering N, Lugering A, Pauels HG, Schulze-Osthoff K, Domschke W et al. (2001). Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol 166: 1344-1351.
47. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. (2006). A common signaling cascade may underlie 00addiction00 to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
48. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. (2008). Contributions of the Raf/MEK/ERK, PI3K/ PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707.
49. Toker A, Yoeli-Lerner M. (2006). Akt signaling and cancer: Surviving but not moving on. Cancer Res 66: 3963-3966.
50. Vakana E, Sassano A, Platanias LC. (2010). Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 6: 966-967.
51. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/ Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
52. Wang SW, Denny TA, Steinbrecher UP, Duronio V. (2005). Phosphorylation of Bad is not essential for PKB-mediated survival signaling in hemopoietic cells. Apoptosis 10: 341-348.
53. Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P et al. (2002). Pharmacologic mitogen-Activated protein/extracellular signal-regulated kinase kinase/mitogen-Activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62: 188-199.
54. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C et al. (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512.